FBIOP
Fortress Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$18.75
+1.02%Aug 13, 2026, 20:05 UTC
Crystalys Therapeutics announced a $130 million Series B financing to support late-stage global development and commercialization preparation for dotinurad.
Source:Aug 13, 2026, 05:57 UTC
Fortress Biotech, Inc. held its Q2 2026 earnings call on August 12, 2026.
Jul 27, 2026, 12:00 UTC
Crystalys Therapeutics closed a $130 million Series B financing to support clinical development of dotinurad for gout.
Source: